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Over the past few years, the understanding of stem cells as a potential therapeutic source has signiﬁ-
cantly evolved, and the previous concept of irreparable neural injury is being reconsidered. Stem cells are
pluripotent cells with high differentiation potential. Induced proliferation and differentiation of these
cells under optimal in vitro conditions has been used to generate different transplantable cells of various
types and stages of development. For spinal cord injury recovery, the human embryonic stem cells and,
recently, the human induced pluripotent stem cells are used as a main source, and two major types of
cells are the target: the oligodendrocytes and motor neurons. The extensive experimental research ef-
forts have focused on translating in vitro cellular regeneration of these cells to in vivo transplantation and
survival of the transplants, in order to improve clinical outcomes. In this review, we will discuss the
progressive development of the cellular generation protocols and the locomotor outcome of their
transplantation at sites on spinal cord injury.
© 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2. Stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3. hESC as a source of oligodendrocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.1. Experimental generation of oligodendrocytes from hESC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.2. Locomotor outcome after oligodendrocytes transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4. hESC as a source of motor neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4.1. Experimental generation of motor neurons from hESC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
4.2. Measurement of motor neurons maturation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.3. Locomotor outcome after motor neurons transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
5. Motor neurons and oligodendrocytes derived human induced pluripotent stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
5.1. Neuronal regeneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Conflict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24stitute, 77 Rolling Oaks Drive, Suite 203, Thousand Oaks, CA 91361, USA.
Mortazavi).
GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
N. Adeeb et al. / Translational Research in Anatomy 1 (2015) 17e24181. Introduction
In 1908, Alexander Maksimov, a Russian histologist, proposed
that all the blood cells and the process of hematopoiesis are derived
from hematopoietic stem cells. However, it was not until 1963,
when the Canadian scientists, James E. Till and Ernest A. McCulloch,
for the ﬁrst time, could demonstrate the presence of these stem
cells, in mice bone marrow. Since then, research on the character-
istics and therapeutic applications of these cells has initiated a new
era of medicine.2. Stem cells
Stem cells are non-differentiated cells that have the capability of
proliferation, self-renewal, formation of large numbers of different
types of cells, and regeneration of the already differentiated tissues.
The potency of the stem cells can be determined depending on how
many types of differentiated cells, and of what germ layers, the
stem cells are capable to produce. This is deﬁned as the ‘differen-
tiation potential’. The totipotential stem cells constitute the ﬁrst
line of cells during fetal development following fertilization, and
may give rise to extraembryonic and embryonic cells. Following the
separation of inner and outer cell masses, the cells of the inner cell
mass (embryonic cells) are deﬁned as pluripotential stem cells, and
may give rise to any type of cells from the yet-to-be formed three
germ layers: ectoderm, mesoderm, and endoderm. The cells of the
outer cell mass form the trophoblast supporting the growth of the
embryo. When the germ layers are separated, cells of each layer are
classiﬁed as multipotent, oligopotent, or unipotent, depending on
their differentiation potentials [4]. These higher levels of stem cells
are deﬁned as the adult stem cells (ASC), which are retained inmost
tissues during childhood and adulthood, and, under normal con-
ditions, give rise to that speciﬁc line of cells of the retaining organ.
However, some tissues, for unknown reasons, including brain,
spinal cord, heart, and kidneys, with minor exceptions, do not
maintain their stem cells, which limits their regenerative ability
following injury [17].
Pluripotent stem cells have been an ideal source for cellular
transplantation, due to their extensive proliferation and differen-
tiation potential. Of these cells, embryonic stem cells (ESC), which
are present during early stage of development, have drawn most
attention. More than two decades of intense research onmouse ESC
has provided insight into human ESC (hESC) research despite the
differences between the two types of cells [13]. They have also
provided the proper methods of differentiating mouse ESC into
several clinically relevant neural and non-neural cell types [16].
Thomson et al. [33] were the ﬁrst to isolate the hESC, using fourteen
inner cell masses of in vitro fertilization (IVF)-produced embryos asTable 1
Characteristics and comparison between oligodendrocytes and motor neurons linages.
Oligodendrocytes linage M
First use [22] [1
Inducers RA, Noggin, SHH, AA, EGF, PDGF, FGF, CNTF, IGF, HGF, T3,
puromorphamine
RA
IG
Inhibitors BMP BM
Expressed genetic
markers
Sox8, Sox9, Sox10, Olig1, Olig2, Nkx2.2, Nkx6.2, A2B5, NG2,
PDGF-R, PLP, Ngn3, Gli1, Gli2, OMG, MBP, GalC, RIP, O4, O1
Pa
HO
III
Secreted factors TGF-b1, TGF-b2, activin A, VEGF, BDNF, midkine, SCF e
Integration and
maturation after
transplantation
Yes, at early and late stages Ye
Locomotor
improvement
Yes, only at early stage Ye
Studies on humans No Noa source. These blastocysts have since then constituted the major
source of hESC. Other sources of ESC include nuclear transfer and
therapeutic cloning. Nuclear transfer is achieved by transferring the
nucleus of an adult differentiated egg (containing the DNA to be
cloned) into an enucleated egg, which is then stimulated to form
blastocysts, from which the ESC can be extracted. When nuclear
transfer is performed for therapeutic purposes, using a nucleus of a
somatic cell (e.g. skin cell), it is then called “therapeutic cloning”
[4].
Following expansion, ESC are induced to form different cells of
various stages of differentiation, including neuroepithelial cells,
oligodendrocytes and their progenitors, as well as motor neurons
and their progenitors. In this review, we will focus on the genera-
tion and transplantation of oligodendrocytes and motor neurons,
and their progenitors.
A comparison between experimental generation of oligoden-
drocytes and motor neurons is summarized in Table 1 and Fig. 1.
3. hESC as a source of oligodendrocytes
Oligodendrocytes (OL) are one type of glial cells that provide
support to the central nervous system (CNS), mainly by the for-
mation of the myelin sheath. They extend into high numbers of
branches and sub-branches expanding into sheets of myelin
membranes that wrap around multiple neural axons. This myelin
sheath facilitates the rapid saltatory conduction and insulation of
the nerve cells [9,12]. It also promotes neuronal and axonal survival
by secreting different types of neurotrophic factors [16,22].
Zhang et al. [35] studied the ability of the oligodendrocytes
progenitor cells (OPC) derived from hESC to secrete neurotrophic
factors. Of all the genes tested, 49 growth factors were signiﬁcantly
expressed by OPC. Of these factors, transforming growth factor
(TGF)-b1, TGF-b2, activin A, vascular endothelial (VEGF), brain-
derived neurotrophic factor (BDNF), midkine, and stem cell factor
(SCF) proteinswere of particular interests. These factors were found
to play a remarkable role in neural regeneration and function
restoration [35].
Following spinal cord injury (SCI), signiﬁcant loss of OL and OPC
adds to the deleterious effect of direct trauma and subsequent
inﬂammation and vascular disruption. Therefore, replacement of
these cells has been one of the promising treatment options that
may preserve the axonal function and suppress their progressive
loss.
3.1. Experimental generation of oligodendrocytes from hESC
Potential sources of human OL include aborted fetuses, olfactory
biopsies of the neuroepithelium, and hESC. The latter may provideotor neurons linage
9]
, Noggin, SHH, puromorphamine, SAGA, dorsomorphin, BDNF, CNTF, GDNF, FGF,
F1, AA, cAMP, NT-3, ROCK
P
x6, Sox1, Sox2, Sox3, Nestin, Otx2, NG2, HOXB1, HOXB4, HOXB6, HOXC5, HOXC8,
XC10, HLBX9, Olig2, Nkx2.2, Nkx6.1, Irx3, GFP, HB9, Islet1, islet2, ChAT, MAP2, b
-tubulin, Musashi1, PTCH, Tuj1
s
s
Fig. 1. Experimental generation of oligodendrocytes and motor neurons from human embryonic stem cells. hESC ¼ Human Embryonic Stem Cells; EB ¼ Embryoid Bodies;
NE ¼ Neuroepithelial cells; OPC ¼ Oligodendrocytes progenitors; OL ¼ Oligodendrocytes; MNP ¼ Motor Neurons progenitors; MN ¼ Motor Neurons.
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potentials [30]. The major challenge in this situation is the ability to
produce and isolate high purity OL and OPC from directed differ-
entiation of hESC, and reduce the risk of teratoma formation. The
process of selective proliferation and differentiation of the hESC
into fully mature OL passes through neural embryoid body (EB)
cells, neural progenitor (NP) or neuroepithelial (NE) cells, glial-
restricted precursor (GP) cells, and OPC formation. (See Fig. 1).
Nistor et al. [22] were the pioneers of this ﬁeld, and were able to
direct the hESC differentiation into high purity and functioning OL
and OPC through yellow neurosphere or NE formation. They used a
modiﬁed retinoic acid (RA) caudalizing protocol to induce
restricted differentiation to a multipotent neural lineage, which can
generate neurons, OL, and astrocytes by employing RA exposure,
along with preferential selection of OL lineage cells by media
components. The used glial restriction media (GRM) contained
insulin and insulin-like growth factor (IGF), differentiation factor
triiodothyronin hormone, ﬁbroblast growth factor (FGF), and
epidermal growth factor (EGF), and it played important role in the
proliferation and survival of the OL [22]. Their method generated
about 80% population of OL capable of myelin formation in vivo, but
no highly branched, ramiﬁed and mature OL were reported in vitro.
Markers of the OL differentiation included Olig1, SOX10, A2B5,
nerve/glial antigen 2 (NG2), and platelet derived growth factor
receptor (PDGF-R).
Izrael et al. [12] added Noggin, antagonist of bone morphoge-
netic proteins (BMP), following treatment with RA. The addition of
Noggin turned out to be the key for the development of highly
branched and mature OL in vitro, which also signiﬁcantly enhanced
their capacity to myelinate after transplantation. The RA functionsthrough stimulation of the Nkx2.2 gene that is required for terminal
differentiation of OL. However, the Nkx2.2 needs the Sox10 gene
activation for proper function, which is also an OL-speciﬁc gene,
and is induced by the addition of Noggin at speciﬁc stages of
development [12]. Olig2 transcription factor gene induction is also
an important step in the differentiation of human OL and their
progenitors. Evidences of such role of Olig2 were provided
following its induction using sonic hedgehog (SHH) [10] and inhi-
bition using BMP [12].
Kang et al. [13] used the growth factors EGF and PDGF to induce
the formation of 81%e91% OPC from neural precursors after their
isolation and expansion from the hESC using speciﬁc media. These
progenitors were then treated with the removal of the growth
factors and the addition of the thyroid hormone T3 to generate
mature OL. The formedmature OL represented 81% of the total cells
number.
Hu et al. [11] described a simpler method that included the
removal the G5 supplement media (containing insulin, transferrin,
selenite, biotin, hydrocortisone, FGF, and EGF), which was applied
for a certain period of time, and the addition of the hepatocyte
growth factor (HGF) to enhance the proliferation of neural pro-
genitors derived from hESC and to promote the generation and
maturation of OL. This method yielded OL with high purity (about
80%).
Sundberg et al. [30] introduced a novel method for the gener-
ation of the OL fromhESC using human recombinant growth factors
and extracellular matrix (ECM) proteins. This is in contrast to the
previous protocols that employed animal-derived (Matrigel) media,
which is less suitable for clinical applications in humans. Their ECM
media contained laminin, collagen IV, and nidogen-1 that together
Table 2
Oligodendrocytes linage markers in experimental studies.
Human embryonic stem cells Neuroepithelial cells Oligodendrocytes progenitor cells Oligodendrocytes
SSEA4, OCT4, TRA-1-60, TRA-1-81 Pax6, Nestin, Mash1, OPC Olig1, Olig2, SOX8, SOX9, SOX10, A2B5, NG2, OMG, PDGF-R, Nkx2.2, Nkx6.2,
Gli1, Gli2
PLP, O1, O4, MBP, GalC, RIP
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growth factors used included; FGF, EGF, and ciliary neurotrophic
factor (CNTF) for the initial neural differentiation; PDGF-AA, EGF,
basic FGF (bFGF), CNTF, and IGF-1 to enhance the survival, prolif-
eration, and differentiation of the OL and their precursors. At the
last stage of the cellular maturation, the CNTF, ascorbic acid (AA),
and T3 were added. All these growth factors were associated, in
variant degrees, with the expression of large number of genes,
including PDGF-R, NG2, Nkx2.2, Sox10, Olig1/2, myelin basic pro-
tein (MBP), proteolipid protein (PLP), Ngn3, Sox9, Sox8, Sox10, Gli1,
Gli2, Nkx6.2, oligodendrocyte-myelin glycoprotein (OMG), O4, and
GalC. The expression of these genes was dependent on the stage of
development and cellular differentiation from hESC to fully mature
OL [30] (Table 2).3.2. Locomotor outcome after oligodendrocytes transplantation
In almost all the experimental studies, induced SCI in animal
models, including mice and rats, was the target of the hESC-derived
OL and OPC transplantation. Transplantation of the OL-linage cells,
generated in the experiment of [22], into the Shiverer mice, was
associated with integration and differentiation into functional OL
over a six-week follow-up period. This was evident by the forma-
tion of compacted, multilayered myelin sheath under microscope,
and the expression of MBP, with exclusive distribution within the
white matter of the spinal cord surrounding the site of injection. No
data on the locomotor improvement were included and only early
transplantation was examined.
Keirstead et al. and Faulkner and Keirstead [8,16] transplanted
the OPC into adult rats with induced SCI at early and late phases; 1
and 10 weeks post-injury, respectively. Eight weeks following the
injection at the early phase, at least 55% of the axons around the site
of injury were remyelinated. This is almost 136% more than the
endogenous remyelination in control group. To assess the func-
tional improvements, the Basso, Beattie, Bresnahan Locomotor
Rating Scale (BBB) and the four-parameter kinematic analyses were
used. The latter measures the rear paw stride length, rear paw
stride width, rear paw toe spread, and rear paw rotation. On both
scales, signiﬁcant gradual improvement was noticed with the early
phase transplantation compared to the control group, and persisted
for almost one month following injection. On the other hand, noneTable 3
Experimental generation of oligodendrocytes from hESC and their transplantation.
Study Year Media Factors D
(
Nistor et al. 2005 DMEM/F12, B27 RA, bFGF, EGF, IGF-1, T3
Keirstead et al. 2005 DMEM/F12, B27 RA, bFGF, EGF, IGF-1, T3
Faulkner and
Keirstead
2005 DMEM/F12, B27 RA, bFGF, EGF, IGF-1, T3
Izrael et al. 2007 ITTSPP/B27 RA, Noggin, SHH, bFGF, EGF, T3 >
Kang et al. 2007 DMEM/F12, N2 bFGF, EGF, PDGF, T3 <
Hu et al. 2009 DMEM/F12, N2 RA, SHH, purmorphamine, Noggin,
bFGF, EGF, IGF-1, PDGF
>
Hu et al. 2009 DMEM/F12 HGF >
Sundberg et al. 2010 DMEM/F12, N2 EGF, bFGF, IGF-1, PDGF, CNTF, AA, T3 >
Sharp et al. 2010 DMEM/F12, B27 RA, EGF, FGFof these microscopic and functional improvements were noticed in
the late phase transplantation. The number of transplanted OL
showed no difference in the ultimate outcome.
The limited improvement at the late phase transplantation is
mainly related to the late pathologic changes at the site of SCI,
which limits the OL and OPC migration to the site of injury, and
suppresses their maturation and differentiation. Moreover, forma-
tion of OPC-directed immune response has also been suggested.
These ﬁndings strongly support the therapeutic window theory for
cellular transplantation [1,8,21,27].
Izrael et al. [12] transplanted the Noggin-treated OL into the
brain of Shiverer mice. They were associated with signiﬁcant local
and distant integration and myelination within the brain tissue. In
another study by Sharp et al. [26], they proclaimed that, besides the
ﬁnal result, the progressive improvement in the symptoms was
faster as compared to control group. Their results were recorded
using forelimb movement scores, which measures the forelimb
stride length, proximal forelimb step range, and passed-
perpendicular step frequency. Functional improvement could be
detected as early as 1 week after transplantation.
Cao et al. [3] described the use of neurotrpohic factors, i.e. CNTF,
with the OL transplantation to improve their survival, integration,
and differentiation [3]. Karimi-Abdolrezaee et al. [14] proved that
the combined use of chondroitinase ABC (ChABC) and growth fac-
tors EGF, bFGF, and PDGF-AA with the transplant signiﬁcantly
improved the outcome of OL differentiation, myelination, and
functional outcome of chronic spinal cord injury. The ChABC an-
tagonizes the chondroitin sulfate proteoglycans (CSPG) of the glial
scar, which negatively inﬂuence the long-term survival, migration,
and differentiation of the transplanted cells [14] (Table 3).4. hESC as a source of motor neurons
Motor neurons (MN) are large nerve cells with extensive den-
dritic extension that are located in speciﬁc areas in the nervous
system, including the brain cortex (upper motor neuron), brain-
stem, and spinal cord (lower motor neuron). By their speciﬁc
location, the MN form connecting links between the CNS and
skeletal muscles, and facilitate movement and breathing [23,32].
SCI is associatedwith direct and delayedMN damage and axonal
loss, which most signiﬁcantly contributes to the functionaluration
days)
Purity Recipient Integration and
differentiation
Locomotor improvement
42 >95% Shiverer mice Yes e
42 >95% Rats Yes Signiﬁcant, only at early
stage transplantation
42 >95% Shiverer mice Yes Signiﬁcant, only at early
stage transplantation
70 94% Shiverer mice Yes e
50 81% e e e
50 84% e e e
50 >80% e e e
80 >90% e e e
42 <98% Rats Yes Signiﬁcant
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MN and their progenitors has been proposed as a therapeutic op-
tion. One major source for these cells is the hESC.4.1. Experimental generation of motor neurons from hESC
The process of MN derivation from the hESC can be achieved
using different protocols. As in the case with the OL, the ﬁrst step is
the proper obtainment of the NE cell from the pluripotent hESC.
This can be achieved either directly or with and intermediate
process of EB formation. Then, these NE are used as a source of the
motor neurons progenitors (MNP) and MN. (See Fig. 1).
The ﬁrst experiential generation of MN from hESC was done by
Li et al. [19]. After culturing the hESC in a feeder layer, which allow
their continuous growth in an undifferentiated state, differentia-
tion into NE cells was induced using neural induction medium
consisting of F12/DMEM, N2 supplement, and heparin with or
without bFGF. Two stages of NE cells could be identiﬁed: early and
late stages. The early stage could be identiﬁed with the expression
of Pax6 transcription factor gene but not Sox1. Thus, Pax6 is the
earliest NE marker expressed during neural plate and tube forma-
tion. Both stages expressed Nestin. Even in the late stage, the NE
cells were also positive for Otx2, a homeodomain protein expressed
by forebrain and midbrain cells, but negative for HoxC8, a home-
odomain protein produced by cells in the spinal cord, and engrailed
1 (En1), which is produced by midbrain. Thus, more selective dif-
ferentiation was needed to produce caudal cells. Treating the NE
cells, at early stage, with RA or bFGF was associated with caudali-
zation of the NE cells. BFGF induced also rostral cells formation. The
caudalization of the cells was marked by the expression of HOXB1,
HOXB6, HOXC5, HOXC8, and HOXC10. All of these markers were
induced by bFGF, whereas, HOXC10was not induced by RA. BFGF, in
contrast to RA, also did not eliminate the expression of Otx2.
Following caudalization, inducing ventral neural cell types were
required for MNP formation. This was achieved by treating the
culture with SHH, and was evident by the balanced expression of
Class II (Olig2, Nkx2.2, Nkx6.1) and Class I (Irx3, Pax6) homeo-
domains. Continued exposure to bFGF suppressed the expression of
SHH, class I and class II genes, and subsequently inhibited MN
differentiation. The use of neuronal differentiation medium was
needed at the differentiation stage. It consisted of the neurobasal
medium, N2 supplement, and cAMP in the presence of RA and SHH
for one week. Following the appearance of Olig2-MNP, BDNF, glial-
derived neurotrophic factor (GDNF), IGF-1, and a low concentration
of SHH were added to the medium. The differentiated MN were
characterized by the expression of HB9, Islet1/2, choline acetyl-
transferase (ChAT), MAP2, and b III-tubulin. (Table 4) The authors
concluded that the cells with combined expression of Islet1/2 and
HB9 were likely MN, whereas the cells with negative HB9 and
positive Islet1/2 were likely interneurons. The differentiated cells
represented almost 20% of the culture, and the identity of the
remaining 80% of the cells remained unknown. The duration of the
process ranged from 28 to 35 days.
Shin et al. [28] used the mouse feeder layer for hESC culture,
followed by the DMEM/F12 medium with N2, L-glutamine, peni-
cillin, streptomycin, and bFGF. Following the removal of the feeder
layer, the formed NE were suspended in neurobasal mediumTable 4
Motor neurons linage markers in experimental studies.
Human embryonic stem
cells
Neuroepithelial cells Motor neurons progenitors
SSEA4, OCT4, TRA-1-60,
TRA-1-81
Pax6, Sox1, Nestin, Otx2,
BF1, PITCH
b III-tubulin, MAP2, Islet1, Tuj1, HB
HOXC8, HLBX9, Olig2, Nkx2.2, Nkxsupplemented with L-glutamine, penicillin, streptomycin, B27,
bFGF, and leukemia inhibitory factor (LIF). Differentiated NE cells
were characterized by the expression of Nestin, Musashi1, or SOX 1,
2, and 3. Later on, exposure of the culture to SHH and RA, alongwith
bFGF favored the differentiation into MN. The effect of SHH on the
NE could be predicted by the expression of PTCH, the SHH receptor.
However, it does not necessitate the differentiation into MN. The
effect of the bFGF was found to increase the MNP Olig2 gene
expression, which was further increased by combination of the
three factors. Their combination also signiﬁcantly increased the
expression of HLBX9 gene. However, some of the cultured NE gave
rise toMN evenwithout SHH and RA exposure. This might be due to
continuous exposure to low level of bFGF, but the exact mechanism
could not be deﬁned. To detect the presence of MN within the
culture, their phenotype markers were examined. These markers
included Islet1, Tuj1, and ChAT, and based on this criterion, 20e30%
of the cultures wereMN. The duration of the process was around 53
days.
Singh Roy et al. [29] induced differentiation of the hESC to MN
through EB formation. The EB formation was induced using the
mouse embryonic feeder cells and treated with collagenase type IV.
It was also fed with the KO-medium (KO-DMEM supplemented
with 20% KO-Serum replacement) and bFGF. The EB were then
treated with RA and SHH until the expression of neuronal marker b
III-tubulin. Then, the MN differentiation was induced by the use of
DMEM/F12 media supplemented with N2, GDNF, BDNF or neuro-
trophin (NT4), CNTF, B27, and fetal bovine serum (FBS), and with
continuous application of RA and SHH. The differentiated MN were
identiﬁed by the expression of Islet1, HB9, and ChAT genes. In their
experiment, 37% of b III-tubulin cells were HB9 positive. The co-
expression of the Green Florescent Protein (GFP) and the Hb9
gene in the differentiating MN allowed the use of ﬂuorescence-
activated cell sorting (FACS) for isolation of the MN from the cul-
ture to purity of more than 99%. Their method, although was faster
to conduct and was associated with higher purity ﬁnal selection, it
resulted in less initial proportions of induced MN, and losing 76% of
all potential MN in the target population.
Lee et al. [18] used the F12/DMEM, N2 supplement medium to
induce the neural differentiation of the hESC co-cultured with MS5
stromal cells, and with the addition of Noggin. The formation of the
neural rosette was evident by the expression of Pax6 and Sox1, and,
later, BF1 and Otx2, which are associated with anterior neural
identity. Gbx2 and HoxB4, which marks the posterior neural
identity, were not expressed during this default conditions. Isolated
neural rosettes were then replaced on polyornithine/laminin
coated culture dishes and N2 medium supplemented with Noggin,
AA, and BDNF in the presence of RA and SHH. The addition of RA
and SHH was associated with induced caudalization and ventrali-
zation of the cells, respectively. This was marked by BF1 suppres-
sion and HOXB4 and HOXC8 (caudal identity markers) and Nkx6.1
and Nkx2.2 (ventral identity genes characteristic of the caudal CNS)
up-regulation. With additional culture under the presence of RA
and SSH, genetic expression indicated the formation of MNP
(Nkx6.1, Olig2), early post-mitotic motor neurons (NG2, Isl1), and
more mature MN (ChAT and vesicular acetylcholine transporter).
Many of the cells also expressed somatic MN marker HB9. In the
third step, further differentiation was induced in the same mediumMotor neurons
9, Lim3, HOXB1, HOXB4, HOXB6, HOXC5, HOXC6,
6.1
b III-tubulin, ChAT, HB9, GFP,
Islet1, Tuj1
Table 5
Experimental generation of motor neurons from hESC and their transplantation.
Study Year Media Factors Duration
(days)
Purity Recipient Integration and
differentiation
Locomotor
improvement
Li et al. 2005 DMEM/F12, N2 RA, SHH, GDNF, BDNF, IGF1, cAMP 28e35 20% e e e
Shin et al. 2005 DMEM/F12, N2 RA, SHH, bFGF 53 20-
30%
e e e
Singh Roy
et al.
2005 DMEM/F12, B27 RA, SHH >40 20% e e e
Lee et al. 2007 DMEM/F12, N2 RA, Noggin, SHH, BDNF, GDNF, AA 50 20% Chick embryo
Rats
Yes e
Li et al. 2008 DMEM/F12, N2 Heparin, SHH, puromorphamine, RA, cAMP, GDNF,
BDNF, IGF1
<30 50% e e e
Wada et al. 2009 DMEM/F12, N2,
B27
SHH, SAG, RA, GDNF, BDNF 38 30% e e e
Erceg et al. 2010 DMEM/F12, N2 RA, SHH, GDNF, BDNF, CNTF 38 20% Rats Yes Signiﬁcant
Takazawa
et al.
2012 DMEM/F12 N2 RA, SHH, AA, cAMP, BDNF, GDNF >30 >30% e e e
Fig. 2. Reprogramming of the human induced pluripotent stem cells from adult ﬁbroblasts using pluripotency-related transcription factors (c-MYC, OCT4, KLF4, SOX2).
iPSC ¼ Induced Pluripotent Stem Cells; NE¼Neuroepithelial cells.
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and AA. This led to expression of more mature MN markers,
including ChAT, the gene required for acetylcholine synthesis. Co-
expression of ChAT and HB9 conﬁrmed MN identity of the hESC
progeny, and the additional expression of Lhx3 suggestedMNof the
medial motor column. According to the authors, a single hESC
plated at day 0 on MS5 for neural induction yielded approximately
100 HB9 MN at day 50 with almost 20% efﬁciency.
Li et al. [20] induced the NE cells differentiation using the
DMEM/F12 medium supplemented with N2, Heparin, and cAMP.
RA and SHH were then added to the culture. Purmorphamine was
occasionally used to replace the variable activity and high cost of
SHH, with the same level of action. In contrast to previous pro-
tocols, exposure to SHH was maintained during the MNP Olig2-
cells phase. This exposure increased proliferation of these cells,
but if sustained until the differentiation phase it would suppress
MN formation and induce OL formation. Thus, after maximal pro-
liferation of the Olig2-cells, the SHH may be reduced. BDNF, GDNF,
and IGF-1 were also added to the culture. The differentiated MN
produced this way represented more than 96% of the total hESC-
differentiated progenies, which is the largest percentage pro-
duced so far.
Wada et al. [34] used a 1:1 mix of DMEM/F12 supplemented
with N2 and Neurobasal medium supplemented with B27, with the
addition of Noggin or Dorsomorphin, to induce hESC differentia-
tion. Following the neural rosette formation, differentiation into
MNP and MN was induced by the addition of RA and either SHH or
SAGA (SHH agonist). Higher concentration of RA had no effect on
raising the MN cell numbers. The addition of RA and SHH was also
associated with caudalization of the cells, marked by increased
expression of HOXB4 and the suppression of the BF1. However, no
signiﬁcant difference in the expression level of b III-tubulin was
noticed, suggesting no difference in neurogenesis itself. Similar
results were obtained using SAGA as a substitute to SHH. For further
maturation, the culture was supplemented with BDNF, GDNF, and
NT-3. These mature MN expressed both HB9 and ChAT gene
markers. The authors proclaimed that the use of the FGFneurospheres following the ﬁrst stage of NE cells formation and
before the second stage (neural rosette) may expand the numbers
of the NE cells up to more than 30-fold while preserving the po-
tency of motor neuron differentiation. They also added that this
effect was more signiﬁcant than using an EGF/FGF neurosphere.
That is due to the EGF effect on suppressing the caudalization of the
cells. Their last step included puriﬁcation of the MN from the cul-
ture by gradient centrifugation, which raised the purity of the
isolated MN from 30% to 80%.
Takazawa et al. [32] induced the EB differentiation from hESC
using the DMEM:F12 medium with 20% Knockout Serum Replacer
(KSR), betamercaptoethanol (BME), L-Glutamine and non-essential
Amino Acids (NEAA). Rho-associated kinase (ROCK) inhibitor,
Noggin, and bFGF were added to the culture. The formed EB were
then resuspended on DMEM F:12 medium with N2 supplement,
NEAA, L-Glutamine, Heparin, bFGF, Noggin, and ROCK inhibitor. The
ROCK inhibitor, and Noggin and bFGF were discontinued at days 5
and 10, respectively, and a diluted Wnt3a-L-cell conditioned me-
dium, RA, AA, db-cAMP, and SHHwere added regularly until day 18.
Then Wnt3a-conditioned medium was discontinued, SHH was
increased, and the BDNF was added. At day 25, the medium was
switched to the neural differentiation medium (Neurobasal me-
dium with N2 and B27, L-Glutamine, NEAA, AA, db-cAMP), with
BDNF, GDNF, IGF-1, CNTF, SHH, and RA. The GFP and Hb9 expression
was the marker for differentiated MN appeared around the day 31.
Morphological changes, including soma size, branching, and neu-
rite outgrowth, were also monitored from day 31e40.
4.2. Measurement of motor neurons maturation
Following isolation, functional maturation of the MN, including
their electrical properties, actions potential generation and con-
duction, and the receptive and terminal synaptic function, can be
analyzed. Measurement of the intrinsic membrane properties of
the MN shows more hyperpolarized resting membrane potential
and decreased input resistance with maturation. The generation
and repetitive ﬁring of action potential can be proven using the
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which measure the function of the ion-channels within the cells,
especially the voltage-gated Naþ and Kþ- channels. Other electrical
characteristics including spike frequency adaptation and rebound
action potential ﬁring can also be measured, and are more consis-
tent with spinal MN [32]. The neurotransmitter sensitivity of the
MN can be assessed by applying the desired neurotransmitter, e.g.
GABA, glutamate, dopamine and acetylcholine to the MN culture,
and measuring the resultant current formation [6]. The synaptic
function can also be studied with neighboring neurons [19] and
skeletal muscle cells [34]. This can detect the maturation of the
synaptic vesicles at the axonal terminal, and the consequent up-
regulation of the neurotransmitter (i.e. acetylcholine) receptor at
the post-synaptic membrane. Co-culture of the MN with astrocytes
derived from the respective hESC line has been reported to be
essential for electrophysiological maturation [18].
4.3. Locomotor outcome after motor neurons transplantation
Lee et al. [18] tested the survival capability of MN via trans-
plantation into the spinal cord of a chick embryo. They found that
these cells were able to survive and extend axonal ﬁbers outside the
CNS. The next step was to test their fate in adult CNS. Thus, they
injected the HB9-cells into the ventral spinal cords of 3-month-old
SpragueeDawley rats. Observations at 1 day, 2 weeks, and 6 weeks
after transplantation revealed progressive loss of the HB9 expres-
sion and increase in ChATexpression, which corresponded with the
physiological MN maturation. There was also evidence of extensive
ﬁber outgrowth and cell migration toward the ventral surface of the
spinal cord. However, over the six weeks period, no signs of axonal
outgrowth outside the CNS were addressed [18].
In the study of Erceg et al. [7], the MNP transplantation into rats
with transected spinal cord showed signiﬁcant locomotor
improvement in a 4 months follow-up period. The locomotor
improvement was assessed clinically, where the samples showed
partial recovery of the hindlimb movements, and scored 6 out of 21
on the BBB scale. This was signiﬁcantly higher than the control
group. On the electrophysiological study 4 months after the
transplantation, partial conduction at the site of injury was present,
compared to blind conduction in the controls. Immunohistological
examination at the injection site showed clear evidence that these
progenitors have the capacity to differentiate into mature OL and
neurons in the lesion site. Nevertheless, no evidence of anatomi-
cally and functionally active motor units was seen [7] (Table 5).
In the above experiment, the ﬁrst application of combined
cellular transplantation was documented. Erceg et al. [7] used both
the OL and MNP in rats with transected spinal cord. Over a 4
months follow-up, the functional locomotor recovery showed a
better hindlimb recovery, and signiﬁcantly higher BBB score and
electrophysiological function.
Lastly, transplantation of OL, MN, and their progenitors proved
that the generation of differentiated and highly puriﬁed cell line
from the hESC was associated with decreased risk of tumor for-
mation, i.e. teratoma. It also decreased the risk of undesired dif-
ferentiation, including astrocyte and scar formation, graft-induced
sprouting, and allodynia [27].
5. Motor neurons and oligodendrocytes derived human
induced pluripotent stem cells
During fetal development, the pluripotent stem cells start to
acquire a restricted and speciﬁc potency that gradually becomes
directed towards one cell line generation. For a long time, this
process was considered unidirectional. In 2006, Takahashi and
Yamanaka [31] were able to go back in cellular time byreprogramming adult somatic cells into pluripotent cells similar to
the ESC using deﬁned pluripotency-related transcription factors
(i.e. Oct3/4, Sox2, c-Myc and Klf4). (Fig. 2) These novel types of stem
cells were named “Induced pluripotent stem cells” or iPSC. Since
this ﬁrst description, various studies have been conducted using
different protocols and cells of origin from different species.
However, the main cellular origin is still the skin ﬁbroblast. These
protocols also tried to decrease the risks and health concerns and
obstacles associated with the use of iPSC which include the inte-
gration of transcription factors with oncogenic properties, muta-
genesis from insertion of the genes, the use of viral vectors, and,
lastly, the slow and relatively inefﬁcient reprogramming process
may create a situation that favors incomplete reprogramming
vectors.
The use of these cells is considered an extensive, rapid, and
important advancement that may solve the ethical issue related to
the use of ESC. They may also be used for cell replacement therapy
without requiring immunosuppressive therapy as they represent
an autologous transplant. Moreover, the fact that these cells are
derived from individual patients makes it possible to develop
customized stem cell therapies, generate disease-speciﬁc stem cell
lines, and perform genetic corrections.
The major disadvantages of these cells include their genetic
instability and high teratogenic potential associated with the pro-
cess of reprogramming and culture, and also endogenous within
the cells of origin. These ﬁndings and others suggest that the iPSC
are more carcinogenic than the ESC [2]. However, despite these
ﬁndings, the functional, morphological, and oncogenic manifesta-
tions of these cells and their impact in vivo are still unclear [25].5.1. Neuronal regeneration
As in the case of hESC, human iPSC (hiPSC) are capable of
differentiating towards all neural cell types, including neurons and
glia, which in turn, are used to treat various kinds of neurological
pathologies. Moreover, due to their beneﬁcial characteristics and
despite their potential risks, the hiPSC is becoming an appealing
alternative source for neuronal generation.
Experimental studies on MN [5,15] and OL [24] generation from
ﬁbroblast-derived human iPSC were capable of inducing functional
cells through an intermediate EB, in a process exactly similar to the
hESC. However, none of these cells were tested in vivo.6. Conclusion
Loss of MN, OL, and their progenitors at the site of SCI, represent
a major contributing factor to the ensuing functional deterioration.
Therefore, replacement of these cells has become a topic of
extensive spinal cord research. In early studies, these cells were
derived from the ESC, but with the breakthrough development of
iPSC, the latter have become an alternative source. Up to date, and
despite the promising outcomes of MN and OL transplantation in
animal models of SCI, the popularity of this type of cellular trans-
plantation has decreased, as we can see with the lack of experi-
mental trials in the last two years. Moreover, there were no studies
done on humans. The reason is mostly related to the complexity of
hESC isolation, and the risk associated with the use of iPSC.Conﬂict of interest statement
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